Bruker Corporation

Bruker announced on September 4 that its energy and supercon technologies unit, Bruker Energy & Supercon Technologies (BEST), has entered a supply collaboration with Luvata Materials & Solutions to scale up production of RRP superconductors for magnetic confinement fusion. The deal comes as fusion projects ramp up globally and follows a month after Bruker's core instruments business showed signs of stabilizing. BEST revenue rose 11.9% year over year to $74.2 million in the second quarter, with organic growth of 8.9%, while first-half revenue climbed 12.3% to $141 million, helping expand non-GAAP operating margin to 14.1% from 9% and lifting non-GAAP diluted EPS to $0.49 from $0.32. However, GAAP results swung to a $65.3 million operating loss due to a $134.9 million non-cash goodwill charge, and total company organic revenue growth was only 2.8% in the quarter. The Luvata agreement has no disclosed contract value or timeline, and BEST's revenue is less than 9% of total company revenue, leaving investors to weigh the fusion potential against a still-soft academic market.

Bruker Corporation reported second-quarter 2026 revenue of $839 million, up 5.2% year-over-year, with organic growth of 2.8% or 3.4% excluding U.S. tariff refunds. Non-GAAP diluted EPS surged 53% to $0.49, driven by cost-saving actions, favorable volume mix, and a net U.S. tariff refund benefit that added about $0.06 per share. The company recorded a noncash goodwill impairment charge of $135 million related to its automation and spatial biology businesses, which continued to experience operating losses, resulting in a GAAP diluted loss per share of $0.41. Scientific Instruments segment organic bookings grew 10% year-over-year, marking the fourth consecutive quarter with a book-to-bill ratio above 1.0, while biopharma orders rose more than 20% and semiconductor metrology orders jumped over 50%. Bruker adopted a new operating structure effective July 1, combining BioSpin, Daltonics, and Optics into a Bruker Biosystems Group, and expects an additional $20 million in cost reductions in fiscal year 2027. The company reiterated its full-year 2026 outlook for organic revenue growth of 1% to 2%, non-GAAP operating margin expansion of 250 to 300 basis points, and non-GAAP EPS of $2.10 to $2.15, while noting that about $20 million in semiconductor revenue will shift from the third quarter to the fourth quarter.

The ten research tools and consumables stocks tracked reported mixed first-quarter results, with aggregate revenues beating analysts' consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Mettler-Toledo posted revenues of 947.1 million dollars, up 7.2% year on year and slightly ahead of estimates, though the quarter was mixed overall. Waters Corporation stood out with revenues of 1.27 billion dollars, a 91.5% year-on-year surge that exceeded estimates by 4.5%, and it delivered the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Revvity's revenues of 686.9 million dollars, up 9.3% year on year, missed estimates by 2.6% and it issued full-year guidance below expectations, marking the weakest performance against estimates in the group. Sotera Health Company reported revenues of 280 million dollars, up 10% year on year and beating estimates by 3.6%, while Bruker's revenues of 823.4 million dollars, up 2.7% year on year, topped estimates by 3.4%. Share prices of the group have risen 20.8% on average since the latest earnings results.

JPMorgan maintained an Overweight rating on Bruker Corporation and raised its price target to $65 from $45. Analyst Casey Woodring updated the company model on June 8. The move follows Bruker's presentation of advances in its microbiology and infection diagnostics portfolio at ASM Microbe 2026, including FDA-approved updates to its MALDI Biotyper CA System that now identifies 549 clinically validated microbial species. The company also introduced research-use tools with libraries covering 5,325 species and is developing a rapid antimicrobial susceptibility testing workflow.

Shares of scientific instrument company Bruker jumped 4.2% in morning trading after Barclays raised its price target to $60 and reiterated an Overweight rating. The optimism was driven by Bruker's new mass spectrometry and proteomics products showcased at the ASMS conference, along with a new shelf registration that increases financial flexibility for potential future deals. The stock cooled to $60.87, up 4.2% from the previous close, and is trading near its 52-week high of $62.70.

The research tools and consumables industry reported mixed first-quarter results, with aggregate revenues beating analyst consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Avantor posted flat revenues of $1.58 billion, exceeding estimates by 2.7%, while Waters Corporation saw revenues surge 91.5% to $1.27 billion, the fastest growth among peers. Revvity's revenues rose 9.3% to $686.9 million but missed estimates by 2.6%, and Bruker's revenues grew 2.7% to $823.4 million, topping expectations by 3.4%. Danaher reported a 3.7% revenue increase to $5.95 billion, slightly missing estimates by 0.8%. Share prices across the group have risen an average of 8.5% since the latest earnings releases.

Bruker Corporation has seen its shares rise 50.3% over the past year, outpacing the industry's 42.5% gain and the S&P 500's 28.2% increase. The rally has been driven by strong growth in the BSI NANO segment, where AI-fueled demand for memory chips and advanced packaging pushed semi-metrology revenues above $300 million annually, and by market share gains in preclinical imaging, highlighted by the acceptance of an 18 Tesla preclinical MRI system in the first quarter of 2026. The company repaid $181.3 million of long-term debt, reducing the balance to $1.66 billion, and net leverage declined to 2.9 times. However, adjusted operating margin fell to 10.2% from 12.7% a year earlier, partly due to tariffs and foreign exchange, which reduced adjusted earnings per share by $0.05 in the quarter. The Zacks Consensus Estimate for 2026 earnings per share remains at $2.12, with a long-term growth rate of 14.8%.